Benzinga | Sep 18, 2020 06:04AM EDT

Genetron Reports Will Highlight Data From 18 Studies At European Society for Medical Oncology Congress September 19-21

Genetron Holdings Limited ((&ldquo, Genetron Health&rdquo, or the &ldquo, Company&rdquo, , NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening and companion diagnostics development, and its collaborators will present data from 18 studies at the upcoming European Society for Medical Oncology (ESMO) Virtual Congress 2020 taking place on September 19-21.

The abstracts include 15 studies on translational medicine covering various cancer types and three studies on bioinformatics development. Data that will be highlighted at the ESMO Virtual Congress were generated in collaboration with more than 10 notable cancer centers and clinical hospitals in China. In summary, the abstracts are grouped by four topics as follows:

Chinese population's genetic characteristics:

* Six studies (#3835, #3836, #3898, #3946, #3961, #3965) focus mainly on the characteristic analyses of high-frequency gene mutations and gene rearrangements in the Chinese population. These studies aim at gathering specific data for the Chinese population in order to design precision oncology therapies for the domestic market.

* Three studies (#3434, #3915, and #3938) describe the genetic characteristics such as germline mutations, somatic mutations and precision treatment targets in Chinese patients with pancreatic ductal adenocarcinomas.

Immunotherapies:

* Two studies (#3943 and #4313) focus on the exploration of immunotherapy-associated molecular biomarkers. The Company has found that KMT2C/KMT2D genetic alterations can be used as prognostic indicators for immunotherapy in colorectal cancer and gastric cancer.

* One study (#4161) demonstrates the therapeutic potential of preoperative immunotherapy in combination with chemotherapy for patients with metastatic pancreatic ductal adenocarcinomas.

Biomarker discoveries:

* One study (#3888) uncovered tumor type-specific genetic variations that could serve as biomarkers for prognosis and perioperative monitoring in each tumor type.

* Two studies (#3845 and #4127) evaluated the clinical significance of ONECUT2 gene methylation in the prognosis and diagnosis of upper tract urinary carcinoma.

Optimizing bioinformatics:

* One study (#3771) discusses the establishment of genomic database and bioinformatic workflow to help detect somatic mutations more precisely in the low mappable regions of human genome. One study (#3827) focuses on the utility of HRD detection using somatic mutation patterns, while another study (#3797) reveals that activity of Wnt may be an independent negative prognostic predictor of survival in patients with low grade gliomas. In addition, a set of key feature genes was selected and can be used in clinical setting for prognosis of patients with low grade gliomas.

"We are pleased to showcase our data from 18 research studies at the upcoming ESMO Virtual Congress. These data reflect Genetron Health's broad research focus and capabilities in various cancer types including lung, gastrointestinal, brain, upper tract urinary and others. Additionally, we have advanced our research in understanding certain genomic characteristics of the Chinese population, target selections and validations, as well as further optimization of our bioinformatics," remarked Hai Yan, PhD, the Company's Co-founder and Chief Scientific Officer. "Lung cancer is one of our key focus areas and both the EGFR fusion and RET rearrangement studies could help us further in designing panels to guide clinical treatments. In regards to research studies in gastrointestinal cancer, KMT2C/D mutation findings could potentially be beneficial in identifying colorectal cancer patients for immune checkpoint inhibitor therapies, and gastric cancer patients for other immunotherapies. Furthermore, our research has shown that liquid biopsy plus genetic and epigenetic profiling could help predict the risk of upper tract urinary carcinoma."

The 18 abstracts include:

Abstract TitleNumber3434 Comprehensive molecular profiling of pancreatic ductal adenocarcinoma in Chinese population3771 BLAST-guided mappability knowledgebase facilitates accurate detection of somatic variants3797 Activation of the Wnt/PCP signaling pathway is an adverse prognostic predictor in patients with low grade glioma (LGG)3827 Accurate detection of HRD status in multiple cancer types using somatic mutation pattern3835 Identification of RET Rearrangement in 12888 Chinese Lung Cancer Patients by Next-Generation Sequencing (NGS)3836 A pan-cancer study of GNAQ/GNA11 mutations in Chinese cancer patients3845 A multivariate logistic regression model for detection of upper tract urinary carcinoma in patients with hematuria The Consistency of Mutation Profiles between Treatment-nai:ve3888 Circulating Tumor DNA and Tumor Tissue Mutations in a Multi-Cancer Monitoring Cohort3898 Identification of epidermal growth factor receptor (EGFR) Fusions in a Large Chinese Lung Cancer Population3915 Deleterious germline mutations in patients with pancreatic ductal adenocarcinoma3938 Clinical relevance of somatic and germline alterations in patients with pancreatic ductal adenocarcinoma3943 KMT2C/KMT2D (KMT2C/D): Promising Biomarkers for Immunotherapy in Gastric Cancer3946 Investigation of Osimertinib-Sensitive EGFR Mutations in Brain Tumors3961 The genomic characteristics of JAK family in 11159 Chinese solid tumor patients3965 Genomic alterations of KEAP1/NFE2L2/CUL3(K/N/C) in Chinese lung cancer patients Identification of the methylated ONECUT2 gene through real-time4127 methylation-specific polymerase chain reaction assays for the noninvasive detection of upper tract urinary carcinoma in urine samples4161 Nab-paclitaxel plus S1 with or without Sintilimab in metastatic pancreatic ductal adenocarcinoma: A single center, retrospective study4313 Investigating the potential relationship between KMT2C/KMT2D Mutations and Immune Checkpoint Inhibitor (ICI) in Colorectal Cancer (CRC)